Vaccinex welcomes inquiries from potential scientific collaborators, service clients, and biopharmaceutical development partners. Please contact us at busdev@vaccinex.com or phone (585) 271-2700 for immediate assistance.

Collaboration Partner	Date	Description
Teva Pharmaceuticals	2/27/07	Co-development collaboration in which Teva and Vaccinex will develop and commercialize a novel therapeutic antibody for Multiple Sclerosis (MS) and oncology.
Bayer Schering Pharma	2/10/06	Collaboration to identify disease targets and potentially develop novel therapeutic antibodies for the treatment of cancer.
Biocon Limited	11/18/04	Co-development collaboration in which Biocon and Vaccinex jointly discover, develop and commercialize at least four therapeutic antibody products.
EUSA Pharma	6/29/04	Strategic collaboration to discover and develop novel monoclonal antibodies for the treatment of certain rare hematological diseases. Vaccinex will have the opportunity to participate as a co-development partner in certain markets.
Lonza Biologics	7/11/03	Guaranteed access for Vaccinex and its partners to Lonza’s world-class manufacturing capabilities and the GS Expression system. Joint marketing on world-wide basis.

Business Development Contact:

Business Development
Vaccinex Inc.
1895 Mount Hope Ave.
Rochester, NY 14620
Phone: 585-271-2700 ext. 123
Fax: 585-271-2766
E-mail: busdev@vaccinex.com